Skip to main content
Premium Trial:

Request an Annual Quote

Silicon Genetics Licenses Enterprise-Wide Expression Platform to AstraZeneca

SAN FRANCISCO, Jan. 15 - Silicon Genetics has licensed its enterprise gene-expression analysis platform to AstraZeneca, the company said on Tuesday.


The one-year license includes Silicon Genetics' GeneSpring, GeNet, and Script Editor software.


Financial details of the agreement were not disclosed, though Saeid Akhtari, chief operating officer of Silicon Genetics, called it "our biggest deal to date."


Akhtari said it is the first deal for Silicon Genetics in which a client licensed all of the enterprise products in a single agreement. Usually, pharmaceutical companies will first try out single aspects of an enterprise system under pilot programs.


"AstraZeneca expects to benefit from broader access to Silicon Genetics' informatics technology," said Kenneth Fasman, global head of R&D informatics at AstraZeneca.


Silicon Genetics expects to close two more enterprise system deals with new customers within the first quarter of this year, said Akhtari.


"This is the year of the enterprise [system]", he predicts. "We see a trend toward a global deployment of this technology."


Last September, Silicon Genetics and Optimal Design entered into a distribution agreement under which Silicon Genetics will market Optimal Design's ArrayMiner technology worldwide for use with Silicon's GeneSpring technology.


GeneSpring, a desktop gene-expression analysis software for microarray experiments, accepts data from array/scanner image analysis programs, other databases, spreadsheets, URLs, as well as UniGene, GenBank, and LocusLink databases. Silicon Genetics, meanwhile, released version 4.0 of its technology in April.

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.